Alberto Palacios Cañas
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Alberto Palacios Cañas has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
- Alejandro Raúl Gratacós Gómez
Department of Medicine Facultad de Medicina Ciudad Real Spain
3 shared publications - Elisa Gómez Torrijos
Sección de Alergología del Hospital General Universitario de Ciudad Real, Spain
3 shared publications - Oscar Marcelo González Jimenez
Allergy Section Hospital General Universitario Ciudad Real Spain
2 shared publications - Ana Rojas Parra
SESCAM Centro de Salud Ciudad Real 2 Ciudad Real Spain
1 shared publication Elisa Gómez Torrijos
Sección de Alergología, Hospital General Universitario de Ciudad Real, España
1 shared publication- Francisco Feo Brito
Allergy Section, General Hospital, Ciudad Real, Spain
1 shared publication
Latest Publications
- Open Access
- 21 August 2023
- Published by Colegio Mexicano de Inmunologia Clinica y Alergia, A. C. in Revista Alergia México
- Vol. 70 (3) , 113-120
Reproducibilidad clínica de reacciones de hipersensibilidad a fármacos en pruebas de exposición controlada
Background Diagnosis of drug hypersensitivity bases on detailed clinical history and skin and challenge tests, which may involve an unaffordable risk. Knowing the reproducibility of reactions could help on the decision of performing them according to safety criteria. Objective The aim was to assess the reproducibility of symptoms in drug challenge tests. Methods The study included patients with positive cutaneous or challenge test throughout 2019. For each patient, clinical suspicion according to Karch-Lasagna algorithm was registered. Primary outcome was the reproducibility of symptoms in the provocation tests using a paired analysis of data with McNemar test. Results Eighty nine patients were included, 16 of them presented more than one positive test. Thirty were skin tests positive and 75 reacted to provocation tests. Eighty nine percent of patients who reacted in challenge test were probably or possibly reactors according to Karch-Lasagna scale. Symptoms of initial reaction did not differ from those triggered in challenge tests. Conclusions Karch-Lasagna scale is useful in predicting the response to drug provocation tests. In most of the positive studies, results were suggested by clinical history and no differences were found between symptoms triggered in challenge test and that referred to in the previous reaction.
- 21 August 2023
- Published by Colegio Mexicano de Inmunologia Clinica y Alergia, A. C. in Revista Alergia México
- Vol. 70 (3) , 113-120
Open AccessReproducibilidad clínica de reacciones de hipersensibilidad a fármacos en pruebas de exposición controlada
Background Diagnosis of drug hypersensitivity bases on detailed clinical history and skin and challenge tests, which may involve an unaffordable risk. Knowing the reproducibility of reactions could help on the decision of performing them according to safety criteria. Objective The aim was to assess the reproducibility of symptoms in drug challenge tests. Methods The study included patients with positive cutaneous or challenge test throughout 2019. For each patient, clinical suspicion according to Karch-Lasagna algorithm was registered. Primary outcome was the reproducibility of symptoms in the provocation tests using a paired analysis of data with McNemar test. Results Eighty nine patients were included, 16 of them presented more than one positive test. Thirty were skin tests positive and 75 reacted to provocation tests. Eighty nine percent of patients who reacted in challenge test were probably or possibly reactors according to Karch-Lasagna scale. Symptoms of initial reaction did not differ from those triggered in challenge tests. Conclusions Karch-Lasagna scale is useful in predicting the response to drug provocation tests. In most of the positive studies, results were suggested by clinical history and no differences were found between symptoms triggered in challenge test and that referred to in the previous reaction.
- Open Access
- 24 February 2023
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 12 (5) , 1823
Combined LTP Sublingual and Oral Immunotherapy in LTP Syndrome: Efficacy and Safety
Introduction: SLIT for the treatment of plant food allergies has been demonstrated to be safe but less effective than OIT, but the latter is associated with more adverse reactions. The aim of the study was to evaluate the efficacy and safety of a new protocol starting with SLIT-peach followed by OIT with commercial peach juice in patients with LTP syndrome. Methods: This was a prospective, noncontrolled, open study on patients with LTP syndrome who are not sensitized to storage proteins. SLIT peach ALK was followed by OIT with Granini® peach juice after 40 days of the SLIT maintenance phase. At home, the Granini® juice dose was progressively increased during the 42 days until reaching 200 ml. After achieving the maximum dose, an open oral food challenge was carried out with the food that had caused the most severe reaction. If negative, the patient was instructed to progressively introduce the foods that were avoided before starting immunotherapy at home. Patients were reviewed 1 month later. The quality-of-life questionnaire FAQLQ-AF was completed at the beginning of the study and one month after the final challenge. Results: Forty-five patients were included, most of them with LTP anaphylaxis. Peach SLIT was well tolerated in 80.5%, and OIT with Granini® was well tolerated in 85%, with no severe adverse reactions. The final provocation was successful in 39/45 (86.6%). One month after the final provocation, 42/45 (93.3%) patients had no dietary restrictions. FAQLA-AF was significantly reduced. Conclusions: This combination of peach SLIT and OIT with commercial peach juice provides a new, fast, effective, and safe immunotherapy option for selected patients with LTP syndrome who are not allergic to storage proteins, improving their quality of life. This study suggests that cross-desensitization relative to the nsLTPs of several plant foods can be achieved by using Prup3.
- 24 February 2023
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 12 (5) , 1823
Open AccessCombined LTP Sublingual and Oral Immunotherapy in LTP Syndrome: Efficacy and Safety
Introduction: SLIT for the treatment of plant food allergies has been demonstrated to be safe but less effective than OIT, but the latter is associated with more adverse reactions. The aim of the study was to evaluate the efficacy and safety of a new protocol starting with SLIT-peach followed by OIT with commercial peach juice in patients with LTP syndrome. Methods: This was a prospective, noncontrolled, open study on patients with LTP syndrome who are not sensitized to storage proteins. SLIT peach ALK was followed by OIT with Granini® peach juice after 40 days of the SLIT maintenance phase. At home, the Granini® juice dose was progressively increased during the 42 days until reaching 200 ml. After achieving the maximum dose, an open oral food challenge was carried out with the food that had caused the most severe reaction. If negative, the patient was instructed to progressively introduce the foods that were avoided before starting immunotherapy at home. Patients were reviewed 1 month later. The quality-of-life questionnaire FAQLQ-AF was completed at the beginning of the study and one month after the final challenge. Results: Forty-five patients were included, most of them with LTP anaphylaxis. Peach SLIT was well tolerated in 80.5%, and OIT with Granini® was well tolerated in 85%, with no severe adverse reactions. The final provocation was successful in 39/45 (86.6%). One month after the final provocation, 42/45 (93.3%) patients had no dietary restrictions. FAQLA-AF was significantly reduced. Conclusions: This combination of peach SLIT and OIT with commercial peach juice provides a new, fast, effective, and safe immunotherapy option for selected patients with LTP syndrome who are not allergic to storage proteins, improving their quality of life. This study suggests that cross-desensitization relative to the nsLTPs of several plant foods can be achieved by using Prup3.
- 18 November 2021
- Published by Wiley in Contact Dermatitis
- Vol. 86 (3) , 228-229
Maculopapular rash due to delayed‐type hypersensitivity from bismuth salts
- 18 November 2021
- Published by Wiley in Contact Dermatitis
- Vol. 86 (3) , 228-229
Maculopapular rash due to delayed‐type hypersensitivity from bismuth salts
- 27 July 2021
- Published by Wiley in Contact Dermatitis
- Vol. 85 (6) , 716-717
Severe maculopapular eruption due to pseudoephedrine in a combination drug, with cross‐reactivity to phenylephrine
- 27 July 2021
- Published by Wiley in Contact Dermatitis
- Vol. 85 (6) , 716-717
Severe maculopapular eruption due to pseudoephedrine in a combination drug, with cross‐reactivity to phenylephrine
- 4 December 2020
- Published by Wiley in Contact Dermatitis
- Vol. 84 (6) , 453-454
Allergic contact dermatitis to red tattoo ink with positive patch tests
- 4 December 2020
- Published by Wiley in Contact Dermatitis
- Vol. 84 (6) , 453-454
Allergic contact dermatitis to red tattoo ink with positive patch tests